Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5166)	8/17/1998 2:30:00 PM
From: Vector1	Read Replies (1) \| Respond to of 6136

AIDS DRUGS - PROTEASE INHIBITORS +4% 100.0% 100.0% Crixivan (Merck) -17% 32.1% 32.7% Invirase (Roche) -67% 7.1% 7.3% Viracept (Agouron) +27% 32.1% 32.4% Norvir (Abbott) +45% 14.3% 14.3% Fortovase (Roche) N.M. 12.5% 13.4% ANALYSIS: Scripts for the class slowed to 4% in July. Roche's new entry Fortovase (soft gel Invarase with better bioavailability) gained share at the expense of its own Invirase. Agouron's Viracept fell 0.3% share, but continues to close in on Merck's Crixivan. AIDS DRUGS -

To: Steve Fancy who wrote (5166)	8/18/1998 9:40:00 AM
From: John F Beule	Read Replies (2) \| Respond to of 6136

Steve, you said: "DOW up 112 points and AGPH starts to come along very grudgingly. Maybe weekly scrip data was bad...I'll get it from my broker next time he calls." How exactly does the DOW affect this and other small cap stocks? That's like saying the Clinton trial affects my income, it has no relevance. Let me help you muddle thru the stock price, we are in a time of high anxiety for investors. No one is going to place their money in a stock that has more money betting against it than for it (shorts vs longs). Until that sentiment changes, the stock will be unfairly (IMO) whipped by speculators. Viracept has already proven itself, another load of script data is irrelevant.